Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ANAB vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANAB Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ANAB Overall Winner 6-Pillar Tally: ANAB 3 – 2 BOLD (1 Tie) Matrix Metrics: ANAB 6 – 4 BOLD

As of Nov 20, 2026, AnaptysBio, Inc. (ANAB) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ANAB carries a Unified Composite Score of 54.8/100 (HOLD) at $46.63 (35.7x Forward P/E, 15.0% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ANAB earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. BOLD 36.8/100 SELL) and 1.00β · 34% Vol risk profile, whereas BOLD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ANAB is currently in a Breakdown options structure phase (RSI 45.5); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANAB vs BOLD
ANAB NASDAQ Head-to-Head Winner
AnaptysBio, Inc. Common Stock
Pharmaceutical Preparations
$46.63
-1.62% 1D
Market Cap $1.4B
TTM Revenue $60M
Forward P/E 35.7x
Beta / 30D Vol 1.00β · 34% Vol
Unified Composite Score
54.8 / 100 HOLD
Tech 59.0 Fund 61.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.5 · SMA20: $47.58 · SMA50: $48.88
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (ANAB 3 – 2 BOLD)

Columns: Metric · ANAB · BOLD
1. Valuation Multiples ANAB
Forward P/E 35.7x N/M
Trailing P/E 7.3x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BOLD
Revenue Growth (YoY) -60.3% +0.0%
Earnings Growth (YoY) -78.8% +0.0%
TTM Revenue (USD) $60M N/A
Market Cap $1.4B $56.2M
3. Profitability & Quality ANAB
Gross Margin N/A N/A
Operating Margin 15.0% 0.0%
Net Profit Margin 417.6% 0.0%
Return on Equity (ROE) -114.5% -64.6%
4. Balance Sheet & Cash Flow ANAB
Cash Generation (TTM) $433M -$48M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.51B Net Cash $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 84.5% (18th %ile) N/A (N/A)
Put/Call OI Skew 0.93x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANAB (6) vs BOLD (4)
Institutional Metric ANAB BOLD Criterion Row Edge
Market Capitalization
Scale
$1.4B $56.2M Larger Scale ANAB
Trailing P/E Ratio
Valuation
7.3x N/M Lower Multiple ANAB
Forward P/E Ratio
Valuation
35.7x N/M Lower Multiple ANAB
Revenue Growth (YoY)
Growth
-60.3% +0.0% Higher Growth BOLD
Operating Margin (TTM)
Profitability
15.0% 0.0% Higher Margin ANAB
Net Profit Margin
Profitability
417.6% 0.0% Higher Margin ANAB
Return on Equity (ROE)
Capital Efficiency
-114.5% -64.6% Higher ROE BOLD
52-Week Range Position
Momentum
34% ($33–$73) 62% ($1–$3) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
1.00β · 34% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
54.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite ANAB
Trailing 12M Revenue (USD)
Operating Scale
$60M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$433M ($1.51B Net Cash) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANAB +1.86 pp
ANAB: -3.06% · BOLD: -4.92%
3M Horizon ANAB +1.41 pp
ANAB: -20.21% · BOLD: -21.62%
6M Horizon BOLD +83.02 pp
ANAB: -21.91% · BOLD: +61.11%
1Y Horizon BOLD +75.75 pp
ANAB: +25.99% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANAB vs BOLD. Trailing 12-month operating profitability (ANAB 15.0% vs BOLD 0.0%) and valuation multiples (ANAB 35.7x vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$60M
Gross MarginN/A
Op. Margin15.0%
ROE / Fwd P/E-114.5% · 35.7x
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANAB BREAKDOWN
93d in phase · OBV DISTRIBUTION
Current IV 84.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.93x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ANAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANAB Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANAB vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, AnaptysBio, Inc. (ANAB) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ANAB carries a Unified Composite Score of 54.8/100 (HOLD) at $46.63 (35.7x Forward P/E, 15.0% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ANAB earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. BOLD 36.8/100 SELL) and 1.00β · 34% Vol risk profile, whereas BOLD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ANAB is currently in a Breakdown options structure phase (RSI 45.5); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BOLD leads the Growth & Scale pillar: ANAB posts -60.3% YoY revenue growth and -78.8% YoY earnings growth on $60M TTM revenue (N/A gross margin, 15.0% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANAB generates $60M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, ANAB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

ANAB screens cheaper on headline valuation multiples. ANAB trades at 35.7x Forward P/E, 7.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANAB (-114.5% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ANAB carries 84.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.93x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.00β · 34% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.